Vectura Share Discussion Threads

[jeevsje] 10/2/2021 15:20

HANGZHOU, China, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Hangzhou Chance Pharmaceuticals (“Chance”;), a clinical-stage biotechnology company focusing on discovering, developing and commercializing transformative inhalation therapies for the world’s most debilitating diseases, and Aerami Therapeutics, Inc. (“Aerami”; ), a clinical stage biopharmaceutical company developing inhalation therapies to treat severe respiratory and chronic diseases, announced today that they have signed an exclusive license and development agreement to develop and commercialize Aerami’s drug device combination product candidate (“AER-901̶1;) for the treatment of Pulmonary Arterial Hypertension (“PAH”) in Greater China region (Mainland, Hong Kong, Macau and Taiwan).

Under the terms of the license and collaboration agreement, Chance will be responsible for the overall development and commercialization of AER-901 for PAH in the licensed territory. Aerami will undertake its own PAH clinical development program in the US and other territories for AER-901, pursuant to a worldwide license from Vectura Group plc [LSE: VEC] to develop and commercialize imatinib for the treatment of PAH. Aerami’s program utilizes the commercially available FOX® device from Vectura to deliver imatinib, a tyrosine kinase inhibitor targeting PDGF-Rs, c-ΚΙΤ and BCR-ABL, directly to the lungs. Aerami targets Phase 1 clinical study results for AER-901 by the end of 2021 and initiation of a PAH pivotal trial in early 2022.

Aerami will receive an upfront license fee and is eligible to receive development and commercial milestone payments. Aerami will supply the product to Chance at an agreed transfer price and receive a high single digit royalty on net sales. Chance will be responsible for conducting and financing local clinical trials required to obtain market authorization in China.

“External collaboration is an integral part of our corporate strategy to establish Chance as a leader in inhalation therapies. Chance is committed to develop innovative and game changing therapies for patients in China and the rest of the world. This collaboration expands our pipeline to PAH, a disease with a very poor prognosis despite tremendous progress achieved in the last decade. We believe the inhalation delivery can avoid the side effects of oral imatinib and are very pleased to be able to develop this innovative therapy for PAH patients in the Greater China region,” commented Donghao Chen, Founder and CEO of Hangzhou Chance Pharmaceuticals.

[justiceforthemany] 10/2/2021 14:24

Volume is very light - for whatever reason.

[jeevsje] 10/2/2021 13:40

1 trades in control

[fhmktg] 10/2/2021 08:51

Hope all goes well pob!

[pooroldboy55] 10/2/2021 08:42

Hi Paul
Very interesting,
Have been wondering if it was me who marked you down by mistake should have been a green tick up if not like you can't believe why anyone would mark red ,
Bloody cold here in North oxon. Back in hospital tomorrow told the wife to turn heating off while I'm away !!!!
Cheers ANDREW ( POB )

[fhmktg] 10/2/2021 08:40

If one of VEC delivery inhalers has a general improvement in the delivery of generic versions, then there may be a case for collaboration with a Hikma for efficient use in whole world markets, but I'm not aware if that's the case.Ellipta is a more tempting area?

[fhmktg] 10/2/2021 08:25

If the study passes peer review and is published, it radically changes the therapeutics available to partner vaccines in the long term treatment of Covid19.

[justiceforthemany] 09/2/2021 17:00

Chippenham, UK - 9 February 2021: Vectura Group plc (LSE: VEC) ("Vectura" or "the Group"), an industry-leading inhalation CDMO, plans to announce its Preliminary Results for the year ended 31 December 2020 on Tuesday 9 March 2021.

Will Downie, Chief Executive Officer, and Paul Fry, Chief Financial Officer will host a live webcast and conference call for analysts at 9:30am GMT on the morning of the results.

[justiceforthemany] 08/2/2021 17:13

Hikma update not far off now - 25th Feb - next catalyst?

[elsa7878] 07/2/2021 21:17

Next year's forecast has been reduced since the update from over 6p down to 4.75p. Strip out the cash and it is not too far off 17 x forward earnings. Good value?

[peddlers] 07/2/2021 19:02

I added a few more last week.
Looking at the weekly chart,along with the growth prospects I'm aiming for £2.

[justiceforthemany] 07/2/2021 14:29

M&A often happens when least expected

[diesel] 07/2/2021 14:25

Hi all, my thoughts re chart were purely based on confirmation of the GSK money, worth around 20p on the share price without that we would be bouncing around the 100p mark on primarily organic growth. With pluses and minuses on the product front and CDMO yet to show any sparkling results difficult to see any short term investment case.

[justiceforthemany] 07/2/2021 14:23

The market of course continues to be highly irrational.
Tesla is trading at over 400x earnings
Netflix 90x
Beyond Meat, Teladoc have both soared despite being loss making businesses and having a negative EPS
Yes they may be seen as 'growth' stocks but they will have to go some to justify such ridiculous P/E ratings.

Who decides what is reasonable for a stock P/E wise?
GSK 11x, Centrica 10x, BT 6x, MRW 12x, Pfizer 10x, AT&T 9x

[brucie5] 07/2/2021 14:13

Paul, noted. Further to which, I see the Naked Trader has been building a position initiated last July. He says:

"My holding in Vectura (VEC) continues to rise and I averaged up with more and it
is becoming quite a large holding.

In a bullish statement last week it expected to top expectation and also has had one
of its drugs approved.

It has tons of cash and concluded 18 deals in 2020. Its specialisation on respiratory
drugs looks timely - fair value could easily be 170p plus."

hxxps://www.nakedtrader.co.uk/

[polaris] 07/2/2021 13:12

I don't go back any further than 2 years. The reason is that charts are irrelevant when the company has changed so much in the period in question. The 160+ levels were at the time of the SKP/VEC merger. So many product failures since then from the VEC legacy pool. Charts are meaningless without having a complete understanding of the business. Charts support valuation models, they do not predict them, IMO.

Back in late 2018 to early 2019 i was hopeful that VEC would reach 125 p with what was known on pipeline and developments. It made that level and stalled. Now, any progress is dependent on the new products to market and business development. All of us are less than enamoured with the CDMO to date. That part of the business will drive the future. Charting is pointless if the underlying business that it depends on is flawed.

[brucie5] 07/2/2021 12:58

polaris7 Feb '21 - 11:16 - 11018 of 11018
0 1 0
Let's look at the chart objectively.
----------------------------------------
I'm not sure you can. Chartism is predicated on the idea that patterns repeat (until they don't) and that the chart reveals all information known to the market. Fundamentalists would naturally disagree.

All I can say from my experience is that charts like this one tend to play out. Personally, I see 1.60 as the target, but 1.80 is the fulfilment of the 5 year bowl. VEC has been bullish for 18 months months now, making higher highs.

Obviously you know the company far better than most, and about a million times better than me. But this is what I see.

About 40% return within the year. And of course that doesn't take in to account any offer that might be made for it.

[polaris] 07/2/2021 11:16

Let's look at the chart objectively. VEC is clearly range-bound. The only short term issue is whether the 115 p level holds. If not, you are looking at 107-108 p as the next support level. Resistance will be in the high 120s.

If VEC breaks out of the current trading range to the upside, then it is actually quite tough to predict any target. It is likely the channel top that has formed from highs back to June 2019. That sits in the low 130s.

All you can say today is that VEC is firmly within the uptrend from mid-2019. Seems that you can make any prediction and stick chart-wise on the end of it and it's fine. There is no obvious basis to a 190-200 p target.

[justiceforthemany] 07/2/2021 09:52

diesel you tool that is the long term target here chart wise - of course there are other resistance points along the way! VEC does behave differently to other shares however and is very volatile for a supposed defensive pharma stock.

[polaris] 06/2/2021 11:22

Kyorin reported Q3 results on Thursday.

Flutiform sales came in at just over 10.2 Bn Yen for the year, down 5 % on same point last year. The FY forecast remains at 14.5 Bn Yen. That's close to £100 M projected for the year and will yield both manufacturing and royalty revenues for VEC.

Without new indications, noting that Flutiform was approved for pediatric use in mid-2020 in Japan, the revenues will probably top out around this level in this market. Kyorin are looking at approval in China and it's not clear what the impact of Covid, if any, has been on sales progression during 2020.

[diesel] 05/2/2021 16:51

J........,your last forecast was this, really you’ve no idea!
“ Resistance at 127-128p broken.
Bowl shaped pattern suggests major resistance longer term now at 167-168p but need to get to 150p first!”

[justiceforthemany] 05/2/2021 11:18

Chart does suggest a return to 190p-200p

[brucie5] 05/2/2021 11:01

Paul, don't stop posting! I always read what you say with interest, even if I'm not always invested. however, I have just bought back in this morning on strength of the chart retrace, at just over 1.16. I would have thought this is an ideal trading vehicle if nothing else, as the entire pattern shows a five year bowl to 1.80, with lots of fairly predictable spikes and retraces along the way. In the meantime sitting on a huge cash position.

What am I missing?

[polaris] 05/2/2021 09:49

Who is the blue child who voted down my previous post? Not happy with facts?

I've been posting on VEC and, before it, SKP for over a decade here. I think i might know a thing or two about what does and doesn't need to be released in a RNS.

You can vote this one down too.